Pharm

Nesiritide

search

Nesiritide, Natrecor, Recombinant Human Brain Natriuretic Peptide

  • Background
  1. Janssen Pharmaceuticals discontinued Nesiritide production in U.S. in 2018
  • Indications
  1. Decompensated Congestive Heart Failure
  • Mechanism
  1. Recombinant Human Brain Natriuretic Peptide
  2. Results in venous and arterial vasodilation
  • Dosing
  1. Bolus: 2 mcg/kg IV bolus
  2. Maintenance: 0.01 mcg/kg/min for 24-48 hours
  • Efficacy
  1. Improves CHF symptoms
  2. INCREASES mortality within first 30 days
  3. Sackner-Bernstein (2005) JAMA 293:1900-5 [PubMed]
  • Monitoring
  1. Blood Pressure during administration (Hypotension risk)
  2. Serum Creatinine
  • Adverse Effects
  1. Hypotension
  2. Headache
  3. Nnausea
  4. Back pain
  • Resources
  1. Nesiritide (FDA Report)
    1. https://fda.report/DailyMed/44c45bfe-461f-4398-8f20-ea771b2403ee